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Background & aim: The addition of prebiotics to infant formula modiﬁes the composition of intestinal
microﬂora. Aim of the study was to test the hypothesis that prebiotics reduce the incidence of intestinal
and respiratory infections in healthy infants.
Methods: A prospective, randomized, placebo-controlled, open trial was performed. Healthy infants were
enrolled and randomized to a formula additioned with a mixture of galacto- and fructo-oligosaccharides
or to a control formula. The incidence of intestinal and respiratory tract infections and the anthropo-
metric measures were monitored for 12 months.
Results: Three hundred and forty two infants (mean age 53.7 32.1 days) were enrolled. The incidence of
gastroenteritis was lower in the supplemented group than in the controls (0.12 0.04 vs. 0.29 0.05
episodes/child/12 months; p¼ 0.015). The number of children with more than 3 episodes tended to be
lower in prebiotic group (17/60 vs. 29/65; p¼ 0.06). The number of children with multiple antibiotic
courses/year was lower in children receiving prebiotics (24/60 vs. 43/65; p¼ 0.004). A transient increase
in body weight was observed in children on prebiotics compared to controls during the ﬁrst 6 months of
follow-up.
Conclusions: Prebiotic administration reduce intestinal and, possibly, respiratory infections in healthy
infants during the ﬁrst year of age.
 2009 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.1. Introduction
Infectious diseases are generally less frequent in breast-fed
infants than in formula-fed infants1,2 and this may be due in part to
the peculiar pattern of microbial colonization typical of mother’s
milk.3,4 Prebiotics are deﬁned as ‘‘non-digestible food ingredients
that beneﬁcially affect the host by selectively stimulating the
growth and/or activity of a limited number of bacterial species in
the colon’’.5 Their addition to infant formulas is expected to exert
beneﬁcial effects on health. However, although prebiotics increase: þ39 081 5451278.
nd European Society for Clinical Nthe load of lactobacilli and biﬁdobacteria and make intestinal
microﬂora of formula-fed infants similar to that observed in breast-
fed infants,6–9 it is not clear whether this translates into clinically
relevant effects.
The intestinal microbiota of breast-fed infants is generally
dominated by biﬁdobacteria and lactic acid bacteria, whereas the
intestinal microecology of formula-fed infants is more similar to
that of adults in that it contains heavier loads of Bacteroides,
Clostridia and Enterobacteriaceae.3,4,10 It is now becoming clear
that the intestinal microﬂora is in a symbiotic relationship with the
host and may drive immune imprinting in the early life.11–13
Therefore dietary components that are capable of modifying the
composition of intestinal microbiota may affect the postnatalutrition and Metabolism. All rights reserved.
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link between changes in intestinal microﬂora and prevention of
diseases has been shown for probiotics. Administration of selected
probiotics has been associated with the prevention of gastrointes-
tinal infections14 and with a reduced incidence of respiratory tract
infections.15 We recently reported that administration of Lactoba-
cillus GG reduced the incidence of pulmonary exacerbations and of
hospital admissions in cystic ﬁbrosis patients.16 For prebiotics there
is virtually no evidence of clinical effects.
Despite the wealth of evidence that a galacto/fructo-oligosac-
charide (GOS/FOS) mixture positively affects the intestinal micro-
ﬂora, it is not yet clear whether this results in clinically relevant
effects. Recently it was shown that term infants fed with a formula
supplemented with a prebiotic mixture containing polydextrose,
oligosaccharides and lactulose had growth and stool characteristics
more similar to those of breast-fed infants compared with infants
fed with a standard formula.17 Very recently, a formula supple-
mented with the GOS/FOS mixture signiﬁcantly reduced the
development of atopic dermatitis in high risk infants.18 The same
prebiotic mixture reduced episodes of all types of infections in
infants at risk of atopy.19 We designed this prospective, case-
controlled, randomized study to test the hypothesis that prebiotics
may have clinically relevant effects in a normal infant population.
To this aim, we investigated whether early administration of a GOS/
FOS-containing formula affected the risk of intestinal and/or
respiratory infections in infants.
2. Patients and methods
2.1. Study design
A multicenter, prospective, randomized, placebo-controlled
open trial with two intervention groups was carried out with the
collaboration of family pediatricians. Due to the pilot nature of the
study, and in line with the proposal by participating family pedia-
tricians, an open-study design was applied. Healthy infants aged
between 15 and 120 days were enrolled by 38 pediatric practi-
tioners in 7 Italian regions, after informed consent was obtained
from the parents. The inclusion criteria were gestational age
between 37 and 42 weeks, birth weight greater than 2500 g, and
introduction of formula feeding after at least 15 days of exclusive
feeding withmaternal milk. Exclusion criteria were twins, clinically
signiﬁcant illness of the mother, congenital immunodeﬁciency, any
chronic or progressive diseases, proven or suspected allergy, and
previous intake of pro- or prebiotics. Infants were enrolled when
formula milk was introduced and this was always done indepen-
dently from the study.
Eligible infants were randomly assigned to receive either
a standard infant formula or a prebiotic-supplemented formula for
12 months. The two formulas were identical except for the addition
of a mixture of GOS/FOS in a ratio of 9:1. The concentration of GOS/
FOS was 0.4 g/100 ml and the two formulas showed a similar
osmolality (280 mOsm/l and 290 mOsm/l, respectively). Randomi-
zation was conducted using a random numbers table with a block
design for groups of 10 infants.
Informed consent was obtained from the parents of all enrolled
children. The study was approved by the local ethics committee.
2.2. Study end points
Primary outcome measures were incidence of acute diarrhea,
incidence of upper and lower respiratory tract infections, and
number of antibiotic courses prescribed for respiratory infections.
Acute diarrhea was deﬁned as a stool pattern with 3 or more loose
or watery stools/day lasting at least for 3 days. Otitis, pharyngitis,laryngitis, tracheitis and bronchitis were considered as upper
respiratory tract infections (URTIs). The diagnosis was made by the
family pediatrician based on speciﬁc symptoms, with or without
fever. All episodes of respiratory infections were recorded during
a follow-up of 12 months. Antibiotic courses were also recorded.
Secondary outcome measures, used to assess nutritional adequacy,
were weight, length and head circumference gain. All the param-
eters were recorded at enrolment and weremonitored at 3, 6, 9 and
12 months after enrolment.
2.3. Study protocol
Each infant underwent the routine evaluation by pediatrician
and wasmonitored for 12 months after enrolment. Every 3months,
the routine visit included a medical examination and measure-
ments of weight, length and head circumference by standard
methods.20 Further clinical assessment was performed in case of
gastrointestinal or respiratory symptoms. Primary and secondary
outcome measures were recorded on a speciﬁc case-report form.
2.4. Statistical analysis
The sample sizes required to detect a reduction of 30% in the
incidence of acute diarrhea and of URTI, at a 5% signiﬁcance level
and with 85% of power, included 150 infants for acute diarrhea and
200 infants for URTI per group. These numbers were based on the
expected incidence of 0.5 episodes/year of acute diarrhea in chil-
dren up to 3 years of age and of 5 episodes/year of URTI in children
up to 4 years of age. A total of 342 children were enrolled in the
study (169 in GOS/FOS group and 173 in the control group). A total
of 201 children completed the study (96 in GOS/FOS group and 105
in the control group). The drop out rate at the different follow-up
times was compared using the Kaplan–Meier method. Log-Rank
test showed no signiﬁcant differences (p¼ 0.212). In order to test
a Missing Completely At Random (MCAR) mechanism, at each time
(3, 6, 9, 12 months), the growth parameters of the lost to follow-up
children, taken at the previous follow-up times (respectively, at the
enrolment time and at 3,6 and 9months), were comparedwith that
of the infants who continued the study, using the t-test for inde-
pendent samples and no signiﬁcant differences were detected
(p[ 0.05, data not shown). The lack of any differences in the drop
out pattern of the two groups allowed us to consider in the
statistical analysis of the outcome variables, only those children
who effectively complete the study, thus we perform a per protocol
analysis. However, in order to measure the effective power of the
statistical procedures (based on the reduced sample size), a post-
experimental power analysis was performed. The power curves
were evaluated by using the upper bound of the conﬁdence inter-
vals (with a conﬁdence level of 95%) for the standard deviation of
each outcome variable, assuming that the data were normally
distributed.
The results of the two formula groups were evaluated with the
t-test for anthropometric measurements (results expressed as
means SD) and for the incidence of acute diarrhea and URTI
(results expressed as means SEM). We used the c2 analysis to
compare the proportion of children with URTI and with acute
diarrhea, as well as to compare the rates of antibiotic use in the two
groups. Value of p< 0.05 was considered signiﬁcant.
3. Results
3.1. Baseline features of infants enrolled
Fig. 1 shows the ﬂow chart of enrolled children throughout the
study. A total of 349 infants were assessed for eligibility, 7 were
Total assessed for eligibility
n. 349
Randomized n. 342
Excluded = 7
No meeting inclusion
criteria 
Allocated to the GOS/FOS
group n. 169 
Allocated to the standard formula
group n. 173 
Lost  to follow-up (poor compliance to the protocol) (n=30)
Discontinued intervention (development of CMPI) (n=3) Lost  to follow-up (poor compliance to the protocol) (n=26)Discontinued intervention (development of CMPI) (n=2) 
Visit at 12 months (n.105)Visit at 12 months (n.96)
Completed, per protocol basis
n. 201 
Excluded from
analysis for 
incomplete data or
protocol violation
n. 40   
Excluded from
analysis for
incomplete data or
protocol violation
n. 40    
Fig. 1. Flow chart of children enrolled in the study. A total of 349 infants were assessed for eligibility; 342 infants were assigned randomly to the GOS/FOS formula (n¼ 169 infants)
or to the control formula (n¼ 173 infants).
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were small for gestational age). Thus, the study population con-
sisted of 342 infants who were randomly assigned to the GOS/FOS
formula (n¼ 169 infants) or to the control formula (n¼ 173 infants).
At enrolment, there were no differences between the two groups in
terms of gender, gestational age, mean weight at birth, mean
duration of breastfeeding, mean age, weight, length, head circum-
ference (Table 1). The relative number of children lost to follow-up
was similar in the two groups. Seventy-three infants in the GOS/
FOS group and 68 in the control group failed to complete the study
because of non-compliance and protocol violation (such as early
introduction of weaning or probiotic assumption) or because of
incomplete data, and a total of 201 infants completed the study.
During the ﬁrst 3 months of the study, 3 infants in the GOS/FOS
group and 2 in the standard formula group developed cow’s milk
protein intolerance (CMPI). Therewas no evidence of a cause–effect
relationship between the introduction of enriched formula and
cow’s milk protein intolerance.Table 1
Baseline characteristics of the children enrolled in the study.
GOS/FOS group
(n¼ 169)
Standard formula group
(n¼ 173)
Gender (M/F) 80/89 83/90
Gestational age (weeks) 39.14 1.35 39.83 1.38
Mean weight at birth (g) 3168.7 479.6 32,386 507.53.2. Safety and tolerance
There was no report of major side effects. The stool pattern of
children receiving prebiotics was generally characterized by softer
but not diarrheic stools and in no case was the prebiotic formula
withdrawn.Mean duration of breastfeeding
(day)
60.7 48.5 60.2 48.8
Enrolment parameters
Mean age (days) 54 32.6 53.9 34.1
Mean weight (g) 4645.6 1191 4643.7 1183
Mean length (cm) 55.3 4.3 55.3 4.4
Mean head circumference (cm) 37.7 3.8 37.4 3.8
Data reported as means SD.3.3. Primary outcome measures
As shown in Fig. 2, the rate of diarrheal episode/child was
signiﬁcantly lower in children receiving the GOS/FOS formula than
in controls (0.12 0.04 vs. 0.29 0.05 episodes/child/12 months;
C.I. 95%mean difference – 0.3–0.03; p¼ 0.015) (Fig. 2A). In addition,the number of childrenwith at least 1 episode of acute diarrheawas
signiﬁcantly lower in the GOS/FOS group 10/96 (10.4%) vs. 26/109
(23.8%); p¼ 0.01, RR: 0.44; C.I. 95% RR: 0.22–0.86 (Fig. 2B).
The number of episodes of URTI was lower in the GOS/FOS
group, but the difference was not signiﬁcant (p¼ 0.4). The number
of children with at least 1 episode of URTI was similar in the two
groups. However, among the children with at least 1 episode of
URTI, the number of children with recurrent URTI, deﬁned as more
than 3 episodes of URTI in 12 months, was lower in children fed
with the GOS/FOS formula (17/60 vs. 29/65) and the difference was
close to signiﬁcance (p¼ 0.06; Fig. 3A).
Administration of prebiotics was associated with a lower
number of antibiotic prescription. The mean rate of antibiotic
courses prescribed for children fed with GOS/FOS was signiﬁcantly
lower compared to controls (1.03 0.15 vs. 1.48 0.16; p¼ 0.038;
C.I. 95% mean difference – 0.88–0.02). Moreover, the percent of
children receiving 2 or more antibiotic courses/year was
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Fig. 2. Acute gastroenteritis in children receiving GOS/FOS enriched formula and in controls. Mean number of episodes of gastroenteritis was signiﬁcantly lower in the GOS/FOS
group than in controls (p¼ 0.01) (A). A lower proportion of children with at least 1 episode of gastroenteritis was observed in the GOS/FOS group (p¼ 0.01) (B).
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p¼ 0.004; RR: 0.6; C.I. 95% RR: 0.42–0.82 (Fig. 3B)). The latter
ﬁnding is consistent with the observed reduced number of children
with recurrent URTI in the GOS/FOS group.
The number of lower respiratory tract infections was very low in
both controls and GOS/FOS group (4 vs. 6 episodes, respectively)
and no further evaluation was made.
3.4. Secondary outcome measures
Secondary outcome measures are shown in Fig. 4. The average
growth parameters (i.e., weight, length and head circumference)
were within the normal ranges in both groups. However, the mean
body weight was signiﬁcantly increased at 3 and 6 months of
follow-up, in the GOS/FOS formula group compared to the control
group (p< 0.01), whereas it was similar in the two groups at 9 and
12 months of follow-up (Fig. 4A). Mean body length was signiﬁ-
cantly greater in the GOS/FOS group at 3, 6, 9 and 12 months of
follow-up than in controls (p< 0.05) (Fig. 4B). Mean head circum-
ference was similar in the two groups at 3, 6, 9 and 12 months of
follow-up (data not shown).
4. Discussion
Prebiotic addition to infant formula is associated with increased
costs compared with standard infant formula and it is therefore
important to establish whether this intervention is associated with
clinical effects.
The results of this study provide evidence of an association
between the administration of prebiotics and clinical effects in
healthy infants. The most convincing ﬁnding is the preventive
effect exerted against intestinal infections. This was supported by
the reduction of the total number of diarrheal episodes and of the%
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Fig. 3. Upper respiratory tract infections and antibiotic use in children receiving GOS/FOS en
more than 3 episodes of URTI was observed in the GOS/FOS (A). The percent of children rece
(p¼ 0.02) (B).number of children with at least 1 gastroenteritis episode in those
receiving the enriched formula. In this context, it is noteworthy that
probiotics have been found to give protection against acute
gastroenteritis.14
A less robust but even more interesting observation is the
reduction of respiratory infections. Although the direct parameter
was not signiﬁcantly different between the two groups, all outcome
measures enclosed in the evaluation pointed toward a decreased
incidence of respiratory infections in the GOS/FOS group. The
protective effect by prebiotics was further supported by
the signiﬁcant reduction of antibiotic courses in infants receiving
the enriched formula.
A preventive effect by modiﬁed intestinal microﬂora against
non-intestinal infections is not entirely new. We and others have
observed a lower incidence of respiratory infections after the
administration of probiotics in children at increased risk of respi-
ratory infections,15,16 such as those with cystic ﬁbrosis. Recently it
has been published that the administration of GOS/FOS enriched
formula protects formula-fed infant, at high risk of atopy, against
infections during the ﬁrst 6 months of life.19
Infections of the intestinal or respiratory tract, although of mild
degree in the vast majority of infants, are very frequent and are
associatedwith substantial costs. Preventive strategies are based on
vaccination against the most frequent agents, i.e., inﬂuenza virus
and rotavirus,21,22 whereas speciﬁc therapies are lacking. The
results of our study may open new perspectives in terms of
prevention of frequent infections in infancy through functional
nutrition in early infancy.
However, the preventive effects on infections was not the only
clinical effect we observed. The growth pattern differed between
controls and children of the GOS/FOS group, with the latter
showing a signiﬁcant transient increase in weight and height at 3
and 6 months. Growth parameters of the two groups of childrenStandard formula
GOS/FOS  formula
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Fig. 4. Growth parameters in children receiving GOS/FOS enriched formula and in controls. Children in GOS/FOS group showed a signiﬁcantly higher mean body weight compared
to controls during the ﬁrst 6 months of follow-up (p< 0.01) (A). This difference was not observed at 9 and 12 months of follow-up. Children in GOS/FOS group showed a mean
length signiﬁcantly higher compared to controls at 3, 6, 9 and 12 months of follow-up (p< 0.05) (B).
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contrast, the signiﬁcant difference in length persisted, although it
was of little absolute magnitude. It seems unlikely that the changes
in growth parameters result from fewer infections, rather, a meta-
bolic mechanism could be involved given the capacity of oligosac-
charides to increase intestinal calcium absorption.23 Whether
prebiotics may induce a transient modiﬁcation of a growth
parameter in healthy children remains to be conﬁrmed and does
not beg substantial clinical implications.
Our study has several limitations, the main of which being its
open label design. This was discussed with the pediatricians
involved in the study and it was concluded that a double blind
design was not easily feasible. Both formulas were already
commercially available and the introduction of blinding may have
contributed in reducing the population size. It was eventually
decided to adopt an observational protocol for this study. The
relatively high dropouts, due to a long term observation, did not
allow an intention to treat analysis, but the lack of difference in
dropouts between the two groups and the post-experimental
power analysis conﬁrmed the statistical signiﬁcance of our results.
Although many infant formulas enriched with prebiotics are
commercially available, there is little proof of clinical advantages.
The available data are largely of microbiological nature and based
on the concept of making intestinal microecology of formula-fed
infants similar to that of breast-fed infants. The European Society
for Pediatric Gastroenterology, Hepatology and Nutrition has made
a call for clinical trails on prebiotics in order to produce recom-
mendations on their inclusion in infant formula.24 Prebiotics are
already included in infant formula, which stresses the need for
clinical trials. When investigating the effects of functional nutrition
in healthy subjects, the transfer from animal or experimental
results to clinical applicationmay be hampered by the high number
of variables and confounding factors. Clinical research, may
provide, through ﬁeld studies, answers to the obvious question of
whether investing money to improve infant formula is justiﬁed by
clinically measurable beneﬁts.
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